Welcome to LookChem.com Sign In|Join Free

CAS

  • or

22924-15-8

Post Buying Request

22924-15-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

22924-15-8 Usage

Chemical Properties

clear colorless liquid

Check Digit Verification of cas no

The CAS Registry Mumber 22924-15-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,2,9,2 and 4 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 22924-15:
(7*2)+(6*2)+(5*9)+(4*2)+(3*4)+(2*1)+(1*5)=98
98 % 10 = 8
So 22924-15-8 is a valid CAS Registry Number.

22924-15-8 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Alfa Aesar

  • (A18940)  3-Ethoxybenzaldehyde, 97%   

  • 22924-15-8

  • 2.5g

  • 528.0CNY

  • Detail
  • Alfa Aesar

  • (A18940)  3-Ethoxybenzaldehyde, 97%   

  • 22924-15-8

  • 10g

  • 1806.0CNY

  • Detail

22924-15-8Relevant articles and documents

Dibenzazepine-linked isoxazoles: New and potent class of α-glucosidase inhibitors

Umm-E-Farwa,Ullah, Saeed,Khan, Maria Aqeel,Zafar, Humaira,Atia-tul-Wahab,Younus, Munisaa,Choudhary, M. Iqbal,Basha, Fatima Z.

supporting information, (2021/05/10)

α-Glucosidase inhibition is a valid approach for controlling hyperglycemia in diabetes. In the current study, new molecules as a hybrid of isoxazole and dibenzazepine scaffolds were designed, based on their literature as antidiabetic agents. For this, a series of dibenzazepine-linked isoxazoles (33–54) was prepared using Nitrile oxide-Alkyne cycloaddition (NOAC) reaction, and evaluated for their α-glucosidase inhibitory activities to explore new hits for treatment of diabetes. Most of the compounds showed potent inhibitory potency against α-glucosidase (EC 3.2.1.20) enzyme (IC50 = 35.62 ± 1.48 to 333.30 ± 1.67 μM) using acarbose as a reference drug (IC50 = 875.75 ± 2.08 μM). Structure-activity relationship, kinetics and molecular docking studies of active isoxazoles were also determined to study enzyme-inhibitor interactions. Compounds 33, 40, 41, 46, 48–50, and 54 showed binding interactions with critical amino acid residues of α-glucosidase enzyme, such as Lys156, Ser157, Asp242, and Gln353.

Design, synthesis, biological evaluation and inhibition mechanism of 3-/4-alkoxy phenylethylidenethiosemicarbazides as new, potent and safe tyrosinase inhibitors

Liao, Bing,Mai, Yuliang,Shi, Huahong,Song, Senchuan,Wang, Fei

, p. 369 - 379 (2020/05/14)

Tyrosinase plays important roles in many different disease related processes, and the development of its inhibitors is particularly important in biotechnology. In this study, thirty-nine 3-/4-alkoxyphenylethyli-denethiosemicarbazides were synthesized as novel tyrosinase inhibitors based on structure-based molecular design. Our experimental results demonstrated that thirty-one of them possess remarkable tyrosinase inhibitory activities with IC50 value below 1μM, and 5a, 6e, 6g and 6t did not display any toxicity to 293T cell line at the concentration of 1000μmol/L. According to the inhibitory activities, several compounds were selected for detail investigation on the structure–activity relationships (SARs), mechanisms of enzyme inhibition, inhibitory kinetics and cytotoxicity. In particular, the interaction between the selected inhibitors and the active center of tyrosinase was considered and discussed in detail based on their structural characteristics. Taken together, the results presented here demonstrated that the newly designed compounds are promising candidates for the treatment of tyrosinase-related disorders and further development of them may have significant contribution in biomedical science.

Homoserine lactone derivatives, preparation method thereof and pharmaceutical composition for prevention or treatment of the periodontal diseases containing the same as an active ingredient

-

Paragraph 0259-0262, (2017/04/14)

The present invention relates to homoserine lactone derivatives, optical isomers of the same, or pharmaceutically acceptable salts of the same. The homoserine lactone derivatives in the present invention have excellent properties as a quorum sensing antagonist which hinders communications among bacteria. According to the present invention, the homoserine lactone derivatives can hinder gene expressions of bacteria while effectively blocking formation of biofilm which is known to raise resistance against antibiotics, and suppress propagation of bacteria, thereby being useful as a pharmaceutical composition for preventing or treating periodontal diseases.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 22924-15-8